Reward-related neural activity after low doses of LSD in participants with depressed mood.

J PsychopharmacolJan 13, 2026 (epub)
Clinical ResearchPsychiatry

James Glazer, Hanna Molla, Royce Lee et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized, placebo-controlled study examined reward-related event-related potentials (ERPs) after low-dose LSD in participants with subclinical mild-to-moderate depressed mood (N = 20) and controls with minimal symptoms (N = 19). Participants received LSD (26 μg tartrate) and placebo in two sessions. Compared with placebo, LSD increased late positive potential (LPP) amplitude to loss versus win feedback only among participants with higher baseline depressed mood. This change was associated with more positive acute mood and lower depressed mood 48 hours after the LSD session. Across the full sample, LSD decreased feedback-P3 and LPP amplitude to reward versus neutral feedback.

Key findings

  • LSD (26 μg tartrate), versus placebo, increased LPP amplitude to loss versus win feedback only in participants with higher baseline depressed mood.
  • The LPP effect was associated with acute positive mood effects and lower depressed mood 48 hours after the LSD versus placebo session.
  • Across the full sample, LSD decreased feedback-P3 and LPP amplitude to reward versus neutral feedback.

Why it matters

The findings link low-dose LSD exposure with altered neural responses to reward feedback in people reporting depressed mood, and with short-term mood measures. They offer a possible neurobiological signal relevant to LSD’s proposed antidepressant effects, while also showing that responses differed by baseline mood and by the type of feedback. The results are preliminary rather than evidence of clinical efficacy.

What to keep in mind

The study involved a small sample and assessed mood only during sessions and 48 hours afterward; the authors advise interpreting the findings with caution.

Source

Published in J Psychopharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.